Dr Reddy’s, American Regent And Endo Add Vasopressin Alternatives
Authorized Generic And 505(b)(2) Version Accompany Pre-Mixed Presentation Of Brand
Executive Summary
Hot on the heels of Eagle’s first US generic launch, Dr Reddy’s has launched an authorized generic version of vasopressin at the same time as Endo’s Par Sterile Products has also launched a new pre-mixed ready-to-use presentation of the Vasostrict brand. Meanwhile, American Regent has also launched its 505(b)(2) product referencing Vasostrict.
You may also be interested in...
Multiple Vasostrict ANDAs Rival Eagle In Competitive Market
Amphastar, Amneal and Aurobindo are among ANDA sponsors confirming USFDA approval for generic versions of Endo’s Vasostrict (vasopressin) 20 units/ml single-dose vial – as first mover Eagle Pharmaceuticals remains locked in patent-litigation proceedings with the originator.
Dr Reddy’s Follows Viatris With Second US Nexavar Rival
Hot on the heels of the first US generic Nexavar launch by Viatris, Dr Reddy’s has followed with a second sorafenib rival. The product represents the latest in a string of significant US launches for the Indian company.
Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.